Mobenakin

Drug Profile

Mobenakin

Alternative Names: Interleukin-1 beta mutein; OCT 43

Latest Information Update: 15 Aug 2007

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Chiron Corporation; Otsuka Pharmaceutical
  • Class Interleukins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte macrophage colony stimulating factor agonists; Interleukin 1 inhibitors; Macrophage colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Glioma; Lymphoma; Urogenital cancer

Most Recent Events

  • 18 Feb 1997 Preregistration for Lymphoma in Japan (SC)
  • 20 Nov 1995 OCT 43 is now called mobenakin
  • 02 Nov 1995 Investigation in Urogenital cancer in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top